Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Etrolizumab treatment in Crohn's disease (Bergamot) cohort 1 RNA-seq

ABSTRACT: Etrolizumab treatment in Crohn's disease (Bergamot) cohort 1 RNA-seq

PROVIDER: PRJNA638957 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Efficacy and safety of ustekinumab treatment in patients with Crohn's disease

Project description:UNITI-2 was a phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT01369342) comparing the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.

2022-09-08 | GSE207022 | GEO

RNA-seq of 4 Crohn's disease and 4 control

Project description:mRNA-seq raw data of 4 Crohn's disease and 4 control from colon tissue

2022-01-01 | GSE164871 | GEO

Efficacy and safety of ustekinumab treatment in patients with Crohn's disease

Project description:Efficacy and safety of ustekinumab treatment in patients with Crohn's disease

| PRJNA853329 | ENA

Etrolizumab treatment in Crohn's disease (Bergamot) cohort 1 RNA-seq

Project description:Etrolizumab is an investigational monoclonal antibody that binds the β7 subunit of α4β7 and αEβ7 integrins. The relative contribution of α4β7 and αEβ7 to gut lymphocyte trafficking remains to be characterized. Here we show that αEβ7 is highly expressed on human intestinal CD8+ cytotoxic intraepithelial lymphocytes (IELs) and a small subset of proinflammatory CD4+ T cells. Dual blockade of α4β7 and αEβ7 reduced CD8+ T cell accumulation in the gut to a greater extent than single blockade of either pathway using a photo-convertible mouse model. αEβ7 blockade decreased T cell-epithelial interactions, increased the migratory speed and promoted egress of activated T cells. In Crohn’s disease patients treated with etrolizumab, a reduction of inflammatory genes and cytotoxic IEL gene signatures was observed. Concurrent blockade of α4β7 and αEβ7 increases reduction of cytotoxic IELs and inflammatory T cells in the gut mucosa through a stepwise inhibition of cell migration and tissue retention. The "SAMPLE_ID" sample characteristic is a sample identifier internal to Genentech.

2021-07-23 | GSE152316 | GEO

Fibrotic signatures in Crohn's disease patients

Project description:This study investigates the presence of specific fibrosis-associated gene expression signatures in Crohn's disease patient biopsies.

2022-01-02 | GSE192786 | GEO

RNA-seq of 4 Crohn's disease and 4 control

Project description:RNA-seq of 4 Crohn's disease and 4 control

| PRJNA692234 | ENA

RNA-seq for inflamed and non-inflamed mucosa in patients with Crohn's disease

Project description:To investigate the gene expression profile of inflamed and non-inflamed mucosa in patients with Crohn's disease. To investigate TCR repertoires in the intestinal mucosa, the expression profile of the TCR repertoire gene was analyzed.

2022-07-19 | GSE208303 | GEO

Transcriptomic analysis reveals the dynamic changes of immune responses during the development of creeping fat in Crohn's disease

Project description:In Crohn's disease, creeping fat is the characteristic expansion of mesenteric adipose tissue wrapping around the inflamed intestine. Through a comparative transcriptomic analysis of creeping fat and normal-looking mesenteric adipose tissues from patients with Crohn's disease and non-Crohn's disease, we found that a dynamic transcriptional and cell compositional change occurs during the progression from non-Crohn's disease to Crohn's disease, and finally to creeping fat.

2023-09-06 | GSE227376 | GEO

A "living biobank" of Crohn's Disease

Project description:A "living biobank" of Crohn's Disease

| PRJNA793263 | ENA

Fibrotic signatures in Crohn's disease patients

Project description:Fibrotic signatures in Crohn's disease patients

| PRJNA793174 | ENA